“…More importantly, the generation of patient-specific and disease-specific (4) iPS cells has the potential to greatly impact the future of regenerative medicine, drug development, as well as our basic understanding of specific disease mechanisms. With the fast progress in this field, different reprogramming strategies have been developed, including using nonintegrating adenoviruses (5), two factors with small molecules (6), reprogramming with a polycistronic cassette containing all four factors (7,8), excisable transposons (9,10), and more recently, virus-free plasmid (11,12). However, the majority of these studies use skin fibroblasts as the parental cells, which usually requires at least 4 weeks to expand from a single skin biopsy to get enough starting cells for reprogramming.…”